![BiomX has dosed their first subject in their Phase 1a study of BX002 phage therapy for IBD](https://www.seventure.fr/wp-content/uploads/2019/02/4__104270789-322x211.jpg)
3 November 2020
BiomX has dosed their first subject in their Phase 1a study of BX002 phage therapy for IBD
BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the...